Intellia Therapeutics NTLA Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's accounts receivable?
- Intellia Therapeutics (NTLA) reported accounts receivable of $9.13M in Q1 2026.
- How has Intellia Therapeutics's accounts receivable changed year-over-year?
- Intellia Therapeutics's accounts receivable decreased by 13.1% year-over-year, from $10.5M to $9.13M.
- What is the long-term trend for Intellia Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), Intellia Therapeutics's accounts receivable has grown at a 34.8% compound annual growth rate (CAGR), from $2.13M to $9.47M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.